OncoMatch/Clinical Trials/NCT06710249
Impact of Salovum® and SPC® Flakes on Brain Tumor Induced Edema
Is NCT06710249 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for glioblastoma.
The objective of this clinical trial is to explore the effects of Salovum®, an egg yolk powder enriched with the endogenous protein antisecretory factor, and SPC® flakes , hydrothermically processed oats, on cerebral edema with clinical symptoms in participants with brain tumors. The primary questions the trial seeks to answer are: * Can Salovum® and SPC® flakes have effect on clinical symptoms of tumor-induced cerebral edema? * Can Salovum® and SPC® flakes induce regression of radiological edema in tumor-induced cerebral edema Additionally, the study will investigate the impact of Salovum® and SPC® flakes in steroid refractory, steroid naïve cerebral edema and type of barin tumor Researchers will: Evaluate edema change from baseline by MRI after 14 days Evaluate neurological and cognitive symptoms Register dose of steroid medications Participants will: * Ingest Salovum® 11g three times daily for 14 days, thereafter tapered during 14 days * Ingest SPC® flakes 1g/kg daily from day 7
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Performance status
WHO/ECOG 0–2
WHO ECOG performance status 0-2
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06710249 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 79 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages